Six passed. One failed. None are legal yet.

What happened

The Pharmacy Compounding Advisory Committee — PCAC — is the federal advisory panel that recommends whether a bulk drug substance belongs on the section 503A Bulk Drug Substances List. That list is what a 503A compounding pharmacy may lawfully compound with when the substance isn't a component of an FDA-approved drug and has no applicable USP monograph.

The committee evaluates each nomination against a four-factor framework at 21 CFR 216.23(c): physicochemical characterization, safety, effectiveness, and historical use in compounding. Over two days it applied that framework to seven peptides that have become fixtures of the wellness and longevity market.

All seven results

A "nominated indication" is the use under which a substance was evaluated. It is not an FDA finding that the substance is safe or effective for that use, and it is not an approved labeling claim.

What the vote means

That second half is the actual story, and most coverage is skipping it. In the briefing documents FDA prepared before the meeting, agency reviewers recommended against every one of the peptides on the docket. The committee voted the other way.

The objections FDA staff put on the record were substantive, and they're worth knowing because they'll shape the rulemaking that follows:

• Identity. For several of these compounds there is no universally accepted chemical formula. One FDA official summarized the problem as never having faced the question of "what is it?" before.
• Evidence. Reviewers described a general lack of quality data establishing safety and effectiveness.
• Dosing. There is little established dosing data or prescribing guidance to work from.
• Follow-up. The agency noted it has no authority to compel compounders to submit safety data after a substance is listed.

Committee members voting yes generally judged the risks to be low. Members voting no worried about both safety and the signal — that listing could create a false impression that these substances had been evaluated with the same rigor as an FDA-approved drug. That concern is exactly the one a practice owner should carry into patient conversations.

What the vote does not mean

Four things, in order of how often they're being gotten wrong.

1. A recommendation is not a rule

If the FDA accepts the recommendation, the path forward is standard federal rulemaking: publish a proposed rule, open a public comment period (typically 60–90 days), review comments, then issue a final rule. Published estimates for the full sequence run from roughly 8–12 months at the optimistic end to 12–24 months as the typical case. The agency is not obligated to accept the committee's advice at all.

2. These peptides are currently on neither list

In April 2026 the FDA removed BPC-157 and other peptides from Category 2 — the bucket for substances that may present significant safety risks — and scheduled this PCAC meeting. Removal from Category 2 is not the same as addition to Category 1, the list of substances eligible for compounding. The practical status today is neither: a regulatory gap, not a permission. Anyone reading "it came off the restricted list" as "it's approved now" has skipped a step.

3. This was 503A only — office stock was not on the ballot

This distinction matters more for clinics than any other item on this page, because 503B is the pathway that supplies office stock — the standardized inventory a practice keeps on the shelf for in-clinic administration. A favorable 503A outcome, even a final one, would not by itself create a lawful office-stock supply. If you're fuzzy on the difference, our 503A vs 503B guide covers it in plain English.

4. Nothing here validates gray-market sourcing

The research-chemical and "not for human consumption" market has spent the week treating this vote as vindication. It is closer to the opposite. The identity and purity questions FDA raised are precisely the questions an unregulated supply chain cannot answer, and a compounding pathway — if one eventually opens — runs through licensed pharmacies with documentation, not through a website.

What happens next — and what it could mean for the industry

Advisory recommendations are a step, not a verdict, and this one carries unusual tension: the committee went against the agency's own reviewers. That makes the FDA's response genuinely uncertain in a way most adcomm outcomes are not. What follows is the realistic range, flagged as scenarios rather than predictions.

The comment period is where the industry actually gets a voice

If the FDA accepts the recommendation, the next real event is a proposed rule followed by a public comment period — typically 60–90 days. That docket is open to anyone: pharmacies, prescribers, practice owners, professional societies. It is the one formal point where operator-level experience can shape the standards that follow. Practices that care about the outcome should be watching for that filing, not for headlines.

Watch the identity and purity language above everything else

The FDA's sharpest objection wasn't efficacy — it was "what is it?" For several of these compounds there is no universally accepted chemical formula. Any rule that eventually lists them will have to answer that, which means specifications, characterization requirements, and testing expectations. The practical effect: compounders already running disciplined documentation and third-party testing are positioned to comply, and thinly-run operations are not. If a pathway opens, it will likely narrow the field rather than widen it.

503B — office stock — is the fight that matters most for clinics

This vote covered 503A only: patient-specific prescriptions. The economics of an in-clinic program run on 503B office stock, and the FDA has not indicated it will review these substances for that list. Even a favorable final rule on 503A would leave in-office supply where it is today. For most aesthetic and wellness practices, the 503B question is the one to track next.

This is a template, not a one-off

Seven substances were on this docket, but a broader set of peptides was reopened for review earlier in 2026. However the FDA handles these seven — the evidence standard it applies, the indications it accepts, the specifications it demands — becomes the working template for the ones that follow. That is why the reasoning in the proposed rule matters more than the vote tally.

Demand arrives before the rule does

The most predictable consequence is the least regulatory one: patients read "FDA panel approves peptides" and act on it now, while the actual legal status is unchanged and will stay unchanged for a year or more. That gap — between public perception and regulatory reality — is the thing practices have to manage, and it starts immediately. The practices that handle it well will be the ones that can explain the distinction clearly and consistently, without either overselling a recommendation or dismissing a patient's question.

What a practice should actually do this week

Not much operationally. A lot conversationally.

1. Expect the question. This got mainstream coverage. Patients who have never said "peptide" out loud will arrive having read that the FDA approved them. It didn't, and the panel didn't either.
2. Know the tier for each compound your patients name. There are now four distinct buckets: FDA-approved; human data, used off-label; animal data only; and — new as of this week — recommended by an advisory committee but not listed. Confusing the last two is the mistake that will get made most often.
3. Don't restructure anything yet. Any change worth making waits on a final rule. Building a program around a non-binding recommendation is building on a proposal.
4. Watch the docket, not the headlines. The meaningful next signal is whether the FDA publishes a proposed rule, and what it says about identity and purity standards.
5. Re-check your partners' documentation posture. Whatever the rule eventually says, the practices that come out of it cleanly will be the ones who could already document where every compounded preparation came from.